Search Results

Lassen Therapeutics today announced the closing of an oversubscribed Series B financing which raised $85 million.

Lassen Therapeutics presented new preclinical data on LASN01, for treatment of TED, at the American Thyroid Association (ATA) Annual Meeting held in Washington DC, September 27 through October 1, 2023.

Lassen Therapeutics today announced new clinical and preclinical data generated with LASN01 at the 2023 European Respiratory Society (ERS) International Congress and the 45th Annual Meeting of the European Thyroid Association (ETA).

Lassen Therapeutics presented new preclinical and Phase I data of LASN01 for treatment of pulmonary fibrosis, at today’s American Thoracic Society (ATS) Annual Meeting being held in Washington DC.

Lassen Therapeutics, a clinical-stage biotech company developing breakthrough antibody therapeutics as potential treatments for immuno-fibrotic diseases and cancer, will present new preclinical data demonstrating activity of its anti-interleukin-18 binding protein (IL-18BP) antibody and efficacy in combination with anti-PD-1 at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Lassen Therapeutics will present new preclinical and Phase I data of LASN01, a potential first-in-class IL-11 receptor (IL-11R) blocking antibody in development for treatment of pulmonary fibrosis, at the American Thoracic Society (ATS) Annual Meeting being held in Washington DC, May 19-24, 2023.

Lassen Therapeutics today announced the initiation of dosing in a Phase 1 study of LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody.

Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced plans to present a poster on IL-11 receptor-blocking as a novel therapeutic approach for lung fibrosis at the upcoming Keystone Symposia Conference.

Lassen Therapeutics presented new preclinical data on LASN01, a monoclonal antibody targeting IL-11 receptor, in preclinical models of skin fibrosis at the Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado.

Lassen Therapeutics today announced the appointment of Puneet S. Arora, M.D. as Chief Medical Officer.